Tenofovir: Gilead applies for approval; expanded access liberalized.
作者信息
Gilden D
出版信息
AIDS Treat News. 2001 May 11(364):2-3, 1.
PMID:11569959
Abstract
Patients who cannot construct a viable antiretroviral regimen with approved drugs will now have easier access to tenofovir, a drug that is currently experimental but may be approved in about six months. Tenofovir is significant because it appears to maintain its antiretroviral activity, with resistant HIV developing relatively slowly.
摘要
相似文献
1
Tenofovir: Gilead applies for approval; expanded access liberalized.
AIDS Treat News. 2001 May 11(364):2-3, 1.
2
Expanded access.
Proj Inf Perspect. 1999 Sep(28):8.
3
Tenofovir: FDA hearing October 3, public comment deadlines September 26.
AIDS Treat News. 2001 Aug 24(370):3-4.
4
Tenofovir DF expanded access. Criteria for U.S. program.
AIDS Treat News. 2001 Feb 23(360):2-3.
5
Gilead sciences releases Viread.
Surviv News (Atlanta Ga). 2002 Jan:15.
6
Generic Truvada approved.
AIDS Patient Care STDS. 2009 May;23(5):395.
7
Tenofovir: FDA hearing on important new antiretroviral.
AIDS Treat News. 2001 Oct 19(372):2-4.
8
Tenofovir DF on the horizon. Investigational nucleotide reverse transcriptor inhibitor could be on pharmacy shelves soon.
Posit Living. 2001 Aug-Sep;10(5):21.
9
Tenofovir approved: broad indication.
AIDS Treat News. 2001 Oct 26(373):2-3.
10
FDA grants tentative approval to first generic version of antiretroviral Viread.
AIDS Patient Care STDS. 2008 Jan;22(1):86.
Zotero 插件